Selene Therapeutics is developing a new therapeutic strategy for treating refractory epilepsy by regulating the neuronal activity set point by reducing the neuronal mean firing rate. Selene aims to develop small molecules for inhibitors of dihydroorotate dehydrogenase, a mitochondrial enzyme located on the inner mitochondrial membrane that participates in several key cellular homeostatic processes. The company is part of the FuturX biotech incubator in Ness Ziona.